Moving prenatal screening and liquid biopsy forward.
The new standard in prenatal care.
UNITY Complete® leverages our proprietary single-molecule, next-generation sequencing (smNGS) platform to directly assess fetal risk for recessive conditions, aneuploidies, and more — from a single maternal blood sample as early as 9 weeks.
By directly measuring disease-causing mutations in the pregnancy via cfDNA with molecular precision, UNITY identifies approximately 3x more affected pregnancies than traditional screening — all without requiring a partner sample.
The power to see what others miss.
Northstar liquid biopsies use smNGS to deliver unmatched sensitivity and single-molecule precision for therapy selection and treatment monitoring, all from a simple blood draw.
Northstar Select® is the most sensitive liquid biopsy for therapy selection and uncovers ~50% more clinically actionable alterations than other ctDNA tests1. Northstar Response® brings single-molecule precision to treatment monitoring, providing real-time, quantifiable insight to help optimize therapy planning and tracks tumor burden changes down to 0.01% tumor fraction, without requiring tissue.